A Study on Safety and Efficacy of Two Doses of Topiramate as Monotherapy in the Treatment of Newly Diagnosed or Recurrent Epilepsy

Study Description

Go to 

Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Brief Summary:

The purpose of this study is to compare the safety and effectiveness of two doses of topiramate as monotherapy in the treatment of pediatric and adult patients with newly diagnosed or recurrent epilepsy.

Condition or disease	Intervention/treatment	Phase
Epilepsy; Seizures; Epilepsies, Partial; Epilepsy, Generalized; Epilepsy, Tonic-Clonic	Drug: topiramate	Phase 3

Detailed Description:

Topiramate is approved for treating epilepsy in combination with other epilepsy drugs, but not approved for treating epilepsy as sole treatment or in recently diagnosed epilepsy characterized by partial-onset seizures. This is a randomized, double-blind, parallel-group, multicenter study to compare the safety and effectiveness of two doses of topiramate as monotherapy in pediatric and adult patients with newly diagnosed (within 3 months) or recurrent epilepsy (partial-onset or primary generalized tonic-clonic). The study consists of 4 phases: Baseline (assessment of seizure frequency and other eligibility), Open-Treatment (all patients receive 25 milligrams[mg]/day of topiramate for 7 days), Core Double-Blind Phase (patients are randomized to receive either their assigned dose of topiramate of 50mg/day or 400mg/day, or maximum tolerated dose, and then remain, if possible, on that dose for the duration of the double-blind phase; they continue to receive the medication until they experience the first seizure or until 6 months after the last patient is enrolled), and Long-Term Extension Phase (patients continue to receive the medication at maximum tolerated dose, which may be adjusted according to individual tolerability and effectiveness, until either the patient withdraws or the sponsor terminates the study). The study hypothesis is that topiramate will be effective in the treatment of newly diagnosed or recurrent epilepsy in dose-dependent manner. Topiramate tablets (25 milligrams[mg]) daily by mouth in once-daily regimen during the 7-day Open-Treatment Phase; topiramate twice daily for total of 50mg/day or 400mg/day during the Double-Blind Phase.

Study Design

Go to 

Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Study Type :	Interventional (Clinical Trial)
Actual Enrollment :	750 participants
Allocation:	Randomized
Intervention Model:	Parallel Assignment
Masking:	Double
Primary Purpose:	Treatment
Official Title:	A Randomized, Double-Blind, Parallel-Group, Monotherapy Study to Compare the Safety and Efficacy of Two Doses of Topiramate in the Treatment of Newly Diagnosed or Recurrent Epilepsy
Study Start Date :	July 1999
Actual Study Completion Date :	September 2003

Arms and Interventions

Go to 

Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Outcome Measures

Go to 

Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :

1. Time to first seizure (partial onset or generalized tonic-clonic seizure) during the core double-blind phase (excluding taper).

Secondary Outcome Measures :

1. Mean plasma topiramate levels for the high and low topiramate dosing groups; laboratory evaluations, vital signs, visual field testing results, and adverse events during trial

Eligibility Criteria

Go to 

Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Ages Eligible for Study:	Child, Adult, Senior
Sexes Eligible for Study:	All
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

• Weigh >=25 kilograms
• Diagnosis of epilepsy within 3 months prior to study entry or recurrence of epilepsy while off of anit-epileptic drugs
• No more than two documented seizures during the three-month retrospective baseline phase
• may have experienced seizures prior to the three-month, retrospective baseline phase
• Patients with partial-onset seizures, with or without a secondarily generalized component, and generalized seizures, including tonic-clonic (grand mal), tonic, clonic, juvenile myoclonic epilepsy (impulsive petit mal) and myoclonic epilepsy
• Receiving either no other concomitant anti-epileptic drug (AED) or be on one standard AED.

Exclusion Criteria:

• Patients who do not have epilepsy
• Patients with absence (petit mal) or atypical absence seizures, epilepsia paritlis continua, cluster pattern or serial seizures
• Patients with progressive neurological or degenerative disorder
• Patients with significant history of unstable medical diseases
• Patients with a drug allergy or hypersensitivity to carbonic anhydrase inhibitors or sulfa drugs
• Patients with history of alcohol or drug abuse within past one year
• Patients with a history of suicide attempt within past one year.

Contacts and Locations

Go to 

Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Sponsors and Collaborators

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Investigators

Study Director:	Johnson & Johnson Pharmaceutical Research & Development, L.L. C. Clinical Trial	Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

More Information

Go to 

Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Additional Information:

A Study on Safety and Efficacy of Two Doses of Topiramate as Monotherapy in the Treatment of Newly Diagnosed or Recurrent Epilepsy 

ClinicalTrials.gov Identifier:	NCT00231556 History of Changes
Other Study ID Numbers:	CR003259
First Posted:	October 4, 2005
Last Update Posted:	June 8, 2011
Last Verified:	January 2010

Keywords provided by Johnson & Johnson Pharmaceutical Research & Development, L.L.C.:

Epilepsy; Seizures; Parital Epilepsies	Generalized Epilepsy; Tonic-Clonic Epilepsy; Topiramate

Additional relevant MeSH terms:

Epilepsy; Epilepsies, Partial; Epilepsy, Generalized; Epilepsy, Tonic-Clonic; Seizures; Brain Diseases; Central Nervous System Diseases; Nervous System Diseases	Neurologic Manifestations; Signs and Symptoms; Topiramate; Anticonvulsants; Neuroprotective Agents; Protective Agents; Physiological Effects of Drugs; Anti-Obesity Agents